# Postoperative recurrence of pancreatic cancer controlled for 9 months solely by severe carbohydrate restriction: ketogenic diet

**Authors:** Takahiro Einama, Naoto Yonamine, Masaki Hatakeyama, Sho Ogata, Kazuki Kobayashi, Hanae Shinada, Takazumi Tsunenari, Yasuhiro Takihata, Mikiya Takao, Hideki Ueno, Yoji Kishi

PMC · DOI: 10.1007/s12328-025-02221-z · 2025-09-16

## TL;DR

A patient with pancreatic cancer saw suppressed tumor growth for 9 months after switching to a strict ketogenic diet following surgery and other treatments.

## Contribution

Demonstrates that a ketogenic diet may suppress pancreatic cancer recurrence when applied strictly.

## Key findings

- A 60-year-old female's pancreatic cancer recurrence was controlled for 9 months with a ketogenic diet.
- The patient's tumor showed stable disease on CT scans after following the diet.
- The ketogenic diet was used as the sole treatment after other therapies failed.

## Abstract

Carbohydrate restriction (ketogenic diet) is a cancer treatment that reduces energy production by oxidative phosphorylation in mitochondria of cancer cells and increases it through anaerobic glycolysis in cytoplasm. We report a patient in whom progression of pancreatic cancer recurrence was suppressed solely by a ketogenic diet for 9-month post-surgery. A 60-year-old female with a diagnosis of pancreatic cancer underwent pancreatoduodenectomy after 3 cycles of chemotherapy with gemcitabine plus nab-paclitaxel. Multiple pulmonary metastases were observed 22 months after the surgery. We administered gemcitabine plus nab-paclitaxel for 1 year. As the partial response continued for 1 year, we performed radiotherapy for the remnant pulmonary metastases followed by administration of S-1 for 6 months. Ten months after radiotherapy, CT showed exacerbation of the pulmonary metastases. As treatment, she requested severe carbohydrate restriction. After 9 months of the ketogenic diet, CT revealed stable disease. A ketogenic diet may have the therapeutic effect of suppressing tumor progression if strictly applied.

## Linked entities

- **Chemicals:** gemcitabine (PubChem CID 60750), nab-paclitaxel (PubChem CID 36314), S-1 (PubChem CID 1497102)
- **Diseases:** pancreatic cancer (MONDO:0005192)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), pulmonary metastases (MESH:D009362), pancreatic cancer (MESH:D010190)
- **Chemicals:** Carbohydrate restriction (-), gemcitabine (MESH:D000093542)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12630170/full.md

---
Source: https://tomesphere.com/paper/PMC12630170